Analgesics & rebound headache
This article was originally published in The Tan Sheet
Chronic use of OTC analgesics that can lead to "rebound headache" may be situation "where we need to improve the labeling and get better information out to consumers so that they can avoid the problem," FDA Commissioner Mark McClellan, MD/PhD, suggests during Jan. 15 appearance on National Public Radio's Diane Rehm Show. If consumers "are using the product very frequently for headaches, they probably should contact their health professional to see if there is another cause for the recurrent headaches, or if there is a better treatment available," he adds. McClellan's comments were prompted by article suggesting link between rebound headache and analgesic use in the Jan. 12 New York Times. Segment on the issue also aired on ABC TV's 20/20 program Jan. 10...
You may also be interested in...
Coronavirus Notebook: New EMA Review To Contextualize Blood Clot Risk From AZ Jab, EU Gets Earlier Access To More Pfizer Vaccines
Denmark has stopped using the AstraZeneca vaccine completely, while the Canadian regulator is not recommending restrictions in any specific populations. Can a new EMA review provide better context to guide the vaccine’s use in different age groups and gender?
Autolus, Scholar Rock, Rocket and Pfizer have managed to convince the European Medicines Agency that their investigational treatments merit a place on the regulator’s priory medicines scheme.
GlaxoSmithKline has discontinued treatment with its ICOS agonist feladilimab in the Phase II INDUCE-3 trial upon the recommendation of the study’s data monitoring committee, another setback for the big pharma’s plans to become a major force in the cancer therapy area.